<p>Viridian Therapeutics, Inc. (NASDAQ:VRDN - 获取免费报告) 的股价在周一的午盘交易中达到了新的 52 周高点。该公司的股价最高达到 34.00 美元，最后交易价格为 33.91 美元，成交量为 17346 股。该股票之前的收盘价为 32.31 美元。</p>
<p>获取 <strong>Viridian Therapeutics</strong> 的提醒：</p>
<h2>分析师评级变动</h2>
<p>几位研究分析师最近对该股票进行了评论。William Blair 在 12 月 3 日的报告中开始覆盖 Viridian Therapeutics 的股票。他们对该股票给予了 “跑赢大盘” 的评级。Wedbush 在 12 月 10 日的研究报告中将 Viridian Therapeutics 的目标价从 42.00 美元上调至 47.00 美元，并给予该股票 “跑赢大盘” 的评级。加拿大皇家银行在 11 月 6 日的研究报告中将 Viridian Therapeutics 的目标价从 41.00 美元上调至 45.00 美元，并给予该股票 “跑赢大盘” 的评级。Weiss Ratings 在 10 月 8 日的报告中重申了对 Viridian Therapeutics 股票的 “卖出（d-）” 评级。最后，Jefferies Financial Group 在 8 月 25 日的研究报告中开始覆盖 Viridian Therapeutics。他们对该股票给予了 “买入” 评级，并设定了 44.00 美元的目标价。共有 11 位股票研究分析师对该股票给予了 “买入” 评级，1 位给予了 “持有” 评级，1 位给予了 “卖出” 评级。根据 MarketBeat.com 的数据，该股票的平均评级为 “适度买入”，平均目标价为 41.08 美元。</p>
<p><strong>阅读我们对 VRDN 的最新股票分析</strong></p>
<h2>Viridian Therapeutics 股价上涨 4.3%</h2>
<p>该公司的 50 日移动平均价格为 26.78 美元，200 日移动平均价格为 20.64 美元。该公司的速动比率为 11.28，流动比率为 11.28，债务与股本比率为 0.07。该公司的市值为 32.1 亿美元，市盈率为-11.20，贝塔值为 0.86。</p>
<p>Viridian Therapeutics (NASDAQ:VRDN - 获取免费报告) 最近在 11 月 5 日公布了其财报。该公司报告本季度每股收益为（0.34 美元），超出分析师一致预期的（0.82 美元）0.48 美元。该公司本季度的收入为 7057 万美元，而分析师预期为 1621 万美元。Viridian Therapeutics 的股本回报率为-78.50%，净利润率为-426.58%。该公司的季度收入同比增长 81993.0%。研究分析师预计 Viridian Therapeutics, Inc. 本年度每股收益将为-4.03 美元。</p>
<h2>内部买卖</h2>
<p>在其他新闻中，董事会成员 Fairmount Funds Management Llc 于 10 月 23 日购买了 454,545 股该公司的股票。每股的平均购买价格为 22.00 美元，总交易额为 9,999,990.00 美元。完成收购后，该董事直接持有该公司 3914458 股股票，价值约 86118076 美元。此次交易使他们的持股增加了 13.14%。该交易已在向证券交易委员会提交的文件中披露，文件可在此链接查看。内部人士持有该公司 0.65% 的股份。</p>
<h2>机构资金流入和流出</h2>
<p>几家对冲基金最近调整了对 VRDN 的持股。Corton Capital Inc. 在第二季度获得了 Viridian Therapeutics 的新股份，价值 248,000 美元。Moody Aldrich Partners LLC 在第二季度将其在 Viridian Therapeutics 的股份增加了 54.2%。Moody Aldrich Partners LLC 现在拥有 89164 股该公司的股票，价值 1247000 美元，此前在该期间购买了 31323 股。汇丰控股 PLC 在第一季度购买了 Viridian Therapeutics 的新股份，价值约 526,000 美元。Raymond James Financial Inc. 在第一季度将其在 Viridian Therapeutics 的股份增加了 1.4%。Raymond James Financial Inc. 现在拥有 318240 股该公司的股票，价值 4290000 美元，此前在该期间购买了 4453 股。最后，J. Safra Sarasin Holding AG 在第二季度将其在 Viridian Therapeutics 的股份增加了 135.5%。J. Safra Sarasin Holding AG 现在拥有 171119 股该公司的股票，价值 2392000 美元，此前在该期间收购了 98447 股。</p>
<h2>Viridian Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Viridian Therapeutics, Inc. 是一家生物技术公司，致力于发现和开发针对严重和罕见疾病的治疗方案。该公司的产品管线包括 VRDN-001，一种针对胰岛素样生长因子-1 受体的单克隆抗体，目前正在进行治疗甲状腺眼病（TED）的三期临床试验；以及 VRDN-003，一种下一代 IGF-1R 人源化单克隆抗体，针对 IGF-1R，并结合半衰期延长技术用于治疗 TED。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票，胜过 Viridian Therapeutics</li>
<li>CD 计算器：定期存款计算器</li>
<li>3 家将大现金流转化为更大股东收益的公司</li>
<li>内部交易 - 你需要知道的事项</li>
<li>GOOGL 的不可阻挡的势头推动价格目标创下新高</li>
<li>上海证券交易所综合指数是什么？</li>
<li>3 只被低估的机器人股票，准备迎来巨额收益</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 Viridian Therapeutics 吗？</h2>
<p>在考虑 Viridian Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及他们推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Viridian Therapeutics 并不在名单上。</p>
<p>虽然 Viridian Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

VRDN

<p>Viridian Therapeutics（纳斯达克代码：VRDN）达到了新的 52 周高点，交易价格高达 34.00 美元。分析师对该股票给予了 “适度买入” 的平均评级，目标价格为 41.08 美元。该公司报告的收益超出预期，收入同比大幅增长。内部人士和机构活动显示对该股票的兴趣增加。Viridian 的产品管线包括甲状腺眼病的治疗</p>

<p>Viridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report)'s stock price reached a new 52-week high during mid-day trading on Monday . The company traded as high as $34.00 and last traded at $33.91, with a volume of 17346 shares changing hands. The stock had previously closed at $32.31.</p>
<div class="lb-trans"><p>Viridian Therapeutics, Inc. (NASDAQ:VRDN - 获取免费报告) 的股价在周一的午盘交易中达到了新的 52 周高点。该公司的股价最高达到 34.00 美元，最后交易价格为 33.91 美元，成交量为 17346 股。该股票之前的收盘价为 32.31 美元。</p>
</div><p>Get <strong>Viridian Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Viridian Therapeutics</strong> 的提醒：</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>Several research analysts recently commented on the stock. William Blair began coverage on shares of Viridian Therapeutics in a report on Wednesday, December 3rd. They issued an &#34;outperform&#34; rating on the stock. Wedbush lifted their price objective on Viridian Therapeutics from $42.00 to $47.00 and gave the stock an &#34;outperform&#34; rating in a research note on Wednesday, December 10th. Royal Bank Of Canada boosted their price objective on Viridian Therapeutics from $41.00 to $45.00 and gave the stock an &#34;outperform&#34; rating in a research report on Thursday, November 6th. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Viridian Therapeutics in a report on Wednesday, October 8th. Finally, Jefferies Financial Group started coverage on Viridian Therapeutics in a research report on Monday, August 25th. They issued a &#34;buy&#34; rating and a $44.00 price target on the stock. Eleven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of &#34;Moderate Buy&#34; and an average price target of $41.08.</p>
<div class="lb-trans"><p>几位研究分析师最近对该股票进行了评论。William Blair 在 12 月 3 日的报告中开始覆盖 Viridian Therapeutics 的股票。他们对该股票给予了 “跑赢大盘” 的评级。Wedbush 在 12 月 10 日的研究报告中将 Viridian Therapeutics 的目标价从 42.00 美元上调至 47.00 美元，并给予该股票 “跑赢大盘” 的评级。加拿大皇家银行在 11 月 6 日的研究报告中将 Viridian Therapeutics 的目标价从 41.00 美元上调至 45.00 美元，并给予该股票 “跑赢大盘” 的评级。Weiss Ratings 在 10 月 8 日的报告中重申了对 Viridian Therapeutics 股票的 “卖出（d-）” 评级。最后，Jefferies Financial Group 在 8 月 25 日的研究报告中开始覆盖 Viridian Therapeutics。他们对该股票给予了 “买入” 评级，并设定了 44.00 美元的目标价。共有 11 位股票研究分析师对该股票给予了 “买入” 评级，1 位给予了 “持有” 评级，1 位给予了 “卖出” 评级。根据 MarketBeat.com 的数据，该股票的平均评级为 “适度买入”，平均目标价为 41.08 美元。</p>
</div><p><strong>Read Our Latest Stock Analysis on VRDN</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 VRDN 的最新股票分析</strong></p>
</div><h2>Viridian Therapeutics Trading Up 4.3%</h2>
<div class="lb-trans"><h2>Viridian Therapeutics 股价上涨 4.3%</h2>
</div><p>The company's fifty day moving average price is $26.78 and its two-hundred day moving average price is $20.64. The company has a quick ratio of 11.28, a current ratio of 11.28 and a debt-to-equity ratio of 0.07. The company has a market cap of $3.21 billion, a price-to-earnings ratio of -11.20 and a beta of 0.86.</p>
<div class="lb-trans"><p>该公司的 50 日移动平均价格为 26.78 美元，200 日移动平均价格为 20.64 美元。该公司的速动比率为 11.28，流动比率为 11.28，债务与股本比率为 0.07。该公司的市值为 32.1 亿美元，市盈率为-11.20，贝塔值为 0.86。</p>
</div><p>Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last announced its earnings results on Wednesday, November 5th. The company reported ($0.34) earnings per share for the quarter, beating analysts' consensus estimates of ($0.82) by $0.48. The company had revenue of $70.57 million during the quarter, compared to analyst estimates of $16.21 million. Viridian Therapeutics had a negative return on equity of 78.50% and a negative net margin of 426.58%.The firm's revenue for the quarter was up 81993.0% on a year-over-year basis. Research analysts expect that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current year.</p>
<div class="lb-trans"><p>Viridian Therapeutics (NASDAQ:VRDN - 获取免费报告) 最近在 11 月 5 日公布了其财报。该公司报告本季度每股收益为（0.34 美元），超出分析师一致预期的（0.82 美元）0.48 美元。该公司本季度的收入为 7057 万美元，而分析师预期为 1621 万美元。Viridian Therapeutics 的股本回报率为-78.50%，净利润率为-426.58%。该公司的季度收入同比增长 81993.0%。研究分析师预计 Viridian Therapeutics, Inc. 本年度每股收益将为-4.03 美元。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买卖</h2>
</div><p>In other news, Director Fairmount Funds Management Llc purchased 454,545 shares of the firm's stock in a transaction that occurred on Thursday, October 23rd. The shares were acquired at an average price of $22.00 per share, for a total transaction of $9,999,990.00. Following the completion of the acquisition, the director directly owned 3,914,458 shares in the company, valued at approximately $86,118,076. The trade was a 13.14% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at this hyperlink. Insiders own 0.65% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，董事会成员 Fairmount Funds Management Llc 于 10 月 23 日购买了 454,545 股该公司的股票。每股的平均购买价格为 22.00 美元，总交易额为 9,999,990.00 美元。完成收购后，该董事直接持有该公司 3914458 股股票，价值约 86118076 美元。此次交易使他们的持股增加了 13.14%。该交易已在向证券交易委员会提交的文件中披露，文件可在此链接查看。内部人士持有该公司 0.65% 的股份。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Several hedge funds have recently modified their holdings of VRDN. Corton Capital Inc. acquired a new stake in Viridian Therapeutics during the 2nd quarter worth $248,000. Moody Aldrich Partners LLC grew its stake in shares of Viridian Therapeutics by 54.2% during the second quarter. Moody Aldrich Partners LLC now owns 89,164 shares of the company's stock worth $1,247,000 after purchasing an additional 31,323 shares during the period. Hsbc Holdings PLC bought a new stake in Viridian Therapeutics in the first quarter valued at about $526,000. Raymond James Financial Inc. lifted its stake in Viridian Therapeutics by 1.4% in the first quarter. Raymond James Financial Inc. now owns 318,240 shares of the company's stock valued at $4,290,000 after buying an additional 4,453 shares during the period. Finally, J. Safra Sarasin Holding AG raised its position in shares of Viridian Therapeutics by 135.5% in the 2nd quarter. J. Safra Sarasin Holding AG now owns 171,119 shares of the company's stock valued at $2,392,000 after acquiring an additional 98,447 shares during the period.</p>
<div class="lb-trans"><p>几家对冲基金最近调整了对 VRDN 的持股。Corton Capital Inc. 在第二季度获得了 Viridian Therapeutics 的新股份，价值 248,000 美元。Moody Aldrich Partners LLC 在第二季度将其在 Viridian Therapeutics 的股份增加了 54.2%。Moody Aldrich Partners LLC 现在拥有 89164 股该公司的股票，价值 1247000 美元，此前在该期间购买了 31323 股。汇丰控股 PLC 在第一季度购买了 Viridian Therapeutics 的新股份，价值约 526,000 美元。Raymond James Financial Inc. 在第一季度将其在 Viridian Therapeutics 的股份增加了 1.4%。Raymond James Financial Inc. 现在拥有 318240 股该公司的股票，价值 4290000 美元，此前在该期间购买了 4453 股。最后，J. Safra Sarasin Holding AG 在第二季度将其在 Viridian Therapeutics 的股份增加了 135.5%。J. Safra Sarasin Holding AG 现在拥有 171119 股该公司的股票，价值 2392000 美元，此前在该期间收购了 98447 股。</p>
</div><h2>Viridian Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Viridian Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.</p>
<div class="lb-trans"><p>Viridian Therapeutics, Inc. 是一家生物技术公司，致力于发现和开发针对严重和罕见疾病的治疗方案。该公司的产品管线包括 VRDN-001，一种针对胰岛素样生长因子-1 受体的单克隆抗体，目前正在进行治疗甲状腺眼病（TED）的三期临床试验；以及 VRDN-003，一种下一代 IGF-1R 人源化单克隆抗体，针对 IGF-1R，并结合半衰期延长技术用于治疗 TED。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Viridian Therapeutics</li>
<li>CD Calculator: Certificate of Deposit Calculator</li>
<li>3 Companies Turning Big Cash Flow Into Bigger Shareholder Gains</li>
<li>Insider Trading - What You Need to Know</li>
<li>GOOGL's Unstoppable Momentum Drives Price Targets to Record Highs</li>
<li>What is the Shanghai Stock Exchange Composite Index?</li>
<li>3 Underrated Robotics Stocks Poised for Huge Gains</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Viridian Therapeutics</li>
<li>CD 计算器：定期存款计算器</li>
<li>3 家将大现金流转化为更大股东收益的公司</li>
<li>内部交易 - 你需要知道的事项</li>
<li>GOOGL 的不可阻挡的势头推动价格目标创下新高</li>
<li>上海证券交易所综合指数是什么？</li>
<li>3 只被低估的机器人股票，准备迎来巨额收益</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Viridian Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Viridian Therapeutics 吗？</h2>
</div><p>Before you consider Viridian Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Viridian Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viridian Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及他们推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Viridian Therapeutics 并不在名单上。</p>
</div><p>While Viridian Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Viridian Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Viridian Therapeutics（NASDAQ:VRDN）创下 52 周新高 - 你是否应该购买？